A new once-nightly oral medication called AD109 has demonstrated promising results in treating obstructive sleep apnea (OSA) in a major phase 3 clinical trial. OSA is a common sleep disorder where the airway repeatedly becomes blocked during sleep, leading to frequent breathing interruptions and poor sleep quality. AD109 combines two drugs, aroxybutynin and atomoxetine, which work together to address neuromuscular dysfunction that causes the airway to collapse during sleep. The trial, named SynAIRgy, included 646 adults with mild to severe OSA who either couldn't tolerate or had refused continuous positive airway pressure (CPAP) therapy, the standard treatment for OSA. Participants who took AD109 saw a 44% reduction in breathing interruptions, compared to an 18% reduction in those who received a placebo. Additionally, the drug improved oxygen levels and reduced the severity of OSA, with more than 40% of patients moving into a less severe category and 18% achieving complete disease control. The study, published in the American Journal of Respiratory and Critical Care Medicine, found that AD109's benefits were consistent across different patient groups, regardless of disease severity or body type. However, the drug was associated with some side effects, including dry mouth, nausea, insomnia, and difficulty urinating. Approximately 21% of patients stopped taking the medication due to these effects. Despite this, the drug has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA), which is intended to expedite the development and review of drugs that treat serious conditions and fill unmet medical needs. Apnimed, the company developing AD109, has submitted a New Drug Application (NDA) to the FDA, which is a formal request for approval to market the drug. If the NDA is accepted, the FDA is expected to provide a potential PDUFA ( Prescription Drug User Fee Act) target action date in the first quarter of 2027. This date would indicate when the FDA expects to complete its review of the application. The clinical trial findings will also be accompanied by a companion mechanistic review published by the American Thoracic Society, which will provide further insight into how AD109 works at a biological level. If approved, AD109 could offer a new treatment option for people with OSA who struggle with CPAP therapy. This medication could be particularly valuable for those who find CPAP devices uncomfortable or difficult to use consistently. However, like all medications, AD109 will need to be carefully evaluated for its long-term safety and effectiveness before it becomes widely available. The results of this trial represent a significant step forward in the search for alternative therapies for OSA.